Abstract
Patients with chronic congestive heart failure belong to a population with reduced quality of life, poor functional class, and increased risk of mortality and morbidity. In these patients, assessment of invasive hemodynamics both serves therapeutic purposes and is useful for stratification roles. The right heart catheterization has become a cornerstone diagnostic tool for patients in refractory heart failure or cardiogenic shock, as well as for the assessment of candidacy for heart replacement therapies, and the management of patients following mechanical circulatory assist device implantation and heart transplantation.
Highlights
The history of right heart catheterization (RHC) began in 1929, when Dr Werner Forssmann, as a surgical trainee in Germany, advanced a 4 French urinary tract catheter from the antecubital fossa to the right atrium and confirmed the position by fluoroscopy [1]
Invasive hemodynamic monitoring is recommended in patients with respiratory distress or impaired systemic perfusion I C 2013 American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) HF
Ratory biomarkers figure into the schematic, invasive hemodynamic parameters from RHC become a crucial addition to the assessment, especially at the more advanced (C–E) stages of Cardiogenic shock (CS) (Table 5)
Summary
The history of right heart catheterization (RHC) began in 1929, when Dr Werner Forssmann, as a surgical trainee in Germany, advanced a 4 French urinary tract catheter from the antecubital fossa to the right atrium and confirmed the position by fluoroscopy [1]. 2. The role of right heart catheterization and invasive hemodynamic monitoring in patients with acute decompensated heart failure. The role of RHC in the clinical scenarios of a patient with elevated right-side pressures that are not correlated with elevated left-sided filling pressures (e.g., in patients with advanced lung disease and pulmonary hypertension), remains invaluable. CS, defined by clinical presentation and invasive hemodynamic criteria, is characterized by a state of tissue hypoperfusion secondary to inadequate cardiac output (CO) in the absence of hypovolemia [15] (Table 3) Within this context, the utility of RHC in the diagnosis, staging, phenotyping, and monitoring of patients in CS is invaluable, especially in the presence of complex hemodynamic interplays such as valvular disease and/or pulmonary hypertension. Evaluation of concomitant pulmonary The gold standard for PH diagnosis, important to assess response to therapy, mPA, PVR, PCWP, response to hypertension delineate into pre-/post-capillary (or mixed) profile vasodilator challenge
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
